News | Cardiac Imaging | September 09, 2019

ASNC Announces Multisocietal Cardiac Amyloidosis Imaging Consensus

Panel of 26 experts from nine professional cardiology societies release new document to facilitate earlier diagnosis, improved disease management

ASNC Announces Multisocietal Cardiac Amyloidosis Imaging Consensus

September 9, 2019 — The American Society of Nuclear Cardiology (ASNC) published a new expert consensus document along with eight other societies on recommendations for multimodality imaging in cardiac amyloidosis in the Journal of Nuclear Cardiology.  ASNC assembled a writing team of 26 experts in cardiovascular imaging and amyloidosis representing these nine societies: the American College of Cardiology (ACC), the American Heart Association (AHA), the American Society of Echocardiography (ASE), the European Association of Nuclear Medicine (EANM), the Heart Failure Society of America (HFSA), the International Society of Amyloidosis (ISA), the Society of Cardiovascular Magnetic Resonance (SCMR), and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Emerging imaging methods have facilitated earlier diagnosis of cardiac amyloidosis and improved prognostication and management with new treatment options. The diagnostic criteria for cardiac amyloidosis, required updating to include these novel imaging tools.

Cardiac amyloidosis is emerging as an underdiagnosed cause of heart failure and mortality characterized by the deposition of amyloid fibrils (misfolded protein deposits) into myocardial tissue. An ideal non-invasive diagnostic method would identify cardiac involvement in amyloidosis and would also confirm the etiologic subtype. No existing diagnostic tools can provide this information individually, necessitating a multimodality cardiac imaging approach.

The purpose of the new consensus document is to: 

  1. Achieve multisocietal consensus on standardized imaging methods, image acquisition, interpretation and reporting; 
  2. Develop multisocietal consensus criteria for the diagnosis of cardiac amyloidosis combining histopathology, laboratory and imaging features; and 
  3. Define appropriate use of imaging in cardiac amyloidosis. 

The writing group reviewed and summarized available literature for imaging in cardiac amyloidosis, and provided comprehensive expert recommendations regarding the role of imaging in cardiac amyloidosis based on evidence combined with expert opinion.

The joint expert consensus document on imaging cardiac amyloidosis is divided into two parts:

"For the first time, imaging experts conferred with heart failure experts and amyloidosis experts to provide guidance on standardized imaging techniques, diagnostic criteria and appropriate utilization of echocardiography, cardiac magnetic resonance imaging and radionuclide imaging in cardiac amyloidosis. We anticipate that these expert multisocietal consensus recommendations on multimodality imaging in cardiac amyloidosis will standardize the diagnosis and improve the management of this highly morbid and underdiagnosed disease." stated writing chairs, Sharmila Dorbala, M.D., MPH, FASNC, director of nuclear cardiology, Brigham and Women's Hospital; and Jamieson Bourque, M.D., MHS, FASNC, director of nuclear cardiology at the University of Virginia.

Watch a video interview with Dorbala about the new guidelines. 

The experts in the writing group envision the use of these consensus recommendations will improve the clinical care and outcomes of individuals affected by cardiac amyloidosis, particularly with newly approved treatments now available. The literature gaps identified could spur relevant research to broaden the understanding of this complex disease and support future development of imaging guidelines for cardiac amyloidosis.

For more information: www.asnc.org/jnc

Reference

1. Dorbala S., Ando Y., Bokhari S., et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization. Journal of Nuclear Cardiology, published online Aug. 29, 2019. https://doi.org/10.1007/s12350-019-01760-6

2. Dorbala S., Ando Y., Bokhari S., et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2—Diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology, published online Aug. 29, 2019. https://doi.org/10.1007/s12350-019-01761-5

Related Content

Gadolinium based contrast dye in brain MRI

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | January 17, 2020
January 17, 2020 — Bracco Diagnostics Inc., the U.
Videos | RSNA | January 13, 2020
ITN Editor Dave Fornell takes a tour of some of the most innovative new medical imaging technologies displayed on the
MR Solutions cryogen free preclinical MRI
News | Magnetic Resonance Imaging (MRI) | January 09, 2020
January 9, 2020 — MR Solutions is continuing to expand its support network
prostate cancer UCL study
News | Prostate Cancer | January 03, 2020
January 3, 2020 — Nearly one in six deaths from...
Videos | MRI Breast | December 26, 2019
Gillian Newstead, M.D., director of global breast imaging and former professor at the University of Chicago, explains
Feinstein Institutes' Thomas Chaly, Ph.D., poses in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s

Feinstein Institutes' Thomas Chaly, Ph.D., in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s

News | Nuclear Imaging | December 26, 2019
December 26, 2019 — The Feinstein Institutes for Medical R...